Default company panoramic image
08f3ba4b 798d 4e82 b633 b5ebad871b80


Lens scan as prognostic/diagnostic for AD, best-in-class to detect AD 20 years before onset, phase 3 ready, world-class SAB, recap valuation, fast exit timeline

  • Stage Prototype Ready
  • Industry Biotechnology
  • Location Marlborough, MA, USA
  • Currency USD
  • Founded January 2003
  • Employees 4
  • Incorporation Type C-corp
  • Website

Company Summary

Cognoptix is a recap as a major investor is out of money despite best in class clinical data and fast Phase 3 program. Test is ready for commercialization with an ideal profile, fulfilling a profound medical need for early AD identification. New experienced management, new involved world-class SAB, fast moving program with good news flow. Other approaches are far behind. 100m people over 50 generated easy $1b-$2b market assuming 10% penetration